Milestone Pharmaceuticals INC

Milestone Pharmaceuticals Inc. held its annual shareholder meeting on June 10, 2026, approving an amendment to its 2019 Equity Incentive Plan to increase authorized shares and re-electing the board of directors.

Milestone Pharmaceuticals reported Q1 2026 results, highlighting early sales traction for CARDAMYST, securing national formulary coverage, and initiating a Phase 3 trial for AFib-RVR, supported by a strong cash position.

Milestone Pharmaceuticals announced its Q4 and full-year 2025 financial results, highlighting the successful commercial launch of CARDAMYST nasal spray for PSVT and a strong cash position.

Milestone Pharmaceuticals announces the U.S. availability of CARDAMYST (etripamil) nasal spray, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia (PSVT).

Milestone Pharmaceuticals Inc. announced the closing of its previously disclosed royalty sale agreement, receiving $75.0 million from RTW for U.S. etripamil sales royalties.

Milestone Pharmaceuticals announced the European Medicines Agency accepted its Marketing Authorization Application for etripamil nasal spray for PSVT, with a decision expected by Q1 2027.

Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, marking the initial product revenue from CARDAMYST and detailing ongoing clinical development for AFib-RVR.

Milestone Pharmaceuticals reports increased net losses in Q3 2025, driven by commercialization preparations, while advancing etripamil's FDA approval pathway and clinical development for cardiovascular indications.

Milestone Pharmaceuticals reports increased losses but strengthens liquidity with a new $48.7 million public offering and an extended royalty agreement, as its lead drug etripamil nears FDA approval with a December 13, 2025 PDUFA date.

Milestone Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), citing CMC issues.

Milestone Pharmaceuticals reported its Q3 2024 financial results and provided updates on the regulatory progress of its lead product candidate, etripamil.

Milestone Pharmaceuticals reported a net loss of $9.4 million for the second quarter of 2024, alongside updates on their lead product candidate, etripamil.

Milestone Pharmaceuticals Inc. announced FDA approval for its first commercial product, CARDAMYST nasal spray for PSVT, and is advancing etripamil for AFib-RVR while expanding international regulatory efforts.

Milestone Pharmaceuticals Inc. announces its 2024 financial results and awaits the FDA's decision on CARDAMYST for PSVT, expected by March 27, 2025.

Milestone Pharmaceuticals has amended its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Milestone Pharmaceuticals received a refuse-to-file letter from the FDA for its etripamil NDA, but plans to resubmit in the second quarter of 2024 after addressing data clarification requests.

CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Milestone Pharmaceuticals' President and CEO, Joseph Oliveto, filed an amended Form 4 to correct the exercise price of his employee stock options to $1.96.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of Chief Medical Officer David Bharucha's employee stock options.

Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, filed an amended Form 4 to correct the exercise price of 204,000 employee stock options.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of Chief Commercial Officer Lorenz Muller's employee stock option to $1.96.

Milestone Pharmaceuticals Inc. filed an amended Form 4 to correct the exercise price of CFO Amit Hasija's employee stock options to $1.96.

Milestone Pharmaceuticals announces its 2026 Annual Meeting of Shareholders to be held virtually on June 10, 2026.

Milestone Pharmaceuticals will hold its 2025 Annual Meeting of Shareholders virtually on June 10, 2025, with several key proposals up for vote.

Milestone Pharmaceuticals will hold its 2025 Annual Meeting of Shareholders virtually on June 10, 2025, to vote on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Milestone Pharmaceuticals will hold its 2024 Annual Meeting of Shareholders virtually on August 28, 2024, to vote on the election of directors and the appointment of auditors.

Milestone Pharmaceuticals has appointed two new independent directors, Stuart M. Duty and Andrew R. Saik, to its Board of Directors and entered into a cooperation agreement with Alta Fundamental Advisers LLC.

Milestone Pharmaceuticals will hold its 2024 Annual Meeting of Shareholders virtually on August 28, 2024, to vote on director elections and auditor appointment.

RTW Investments, LP and Roderick Wong disclose beneficial ownership of 9.9% of Milestone Pharmaceuticals Inc. common shares, holding 12,356,953 shares.

Adage Capital Management, L.P. has reported beneficial ownership of 8,000,000 common shares of Milestone Pharmaceuticals Inc., representing 6.37% of the class, primarily through warrants.

Trails Edge Capital Partners, LP and affiliates have filed an amended Schedule 13G, disclosing their beneficial ownership in Milestone Pharmaceuticals Inc. has fallen to 4.3%.

Propel Bio Management, Leen Kawas, Richard Kayne, and Propel Bio Partners have disclosed a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc., including shares from a recent offering and warrant exercises.

Trails Edge Capital Partners, LP, along with its affiliates, has disclosed a 9.9% beneficial ownership stake in Milestone Pharmaceuticals Inc., primarily through common shares and exercisable warrants.

RTW Investments, LP and Roderick Wong, M.D. report a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. through a Schedule 13G/A filing.